Over 135 Companies Developing Over 150 Therapies for Non-Small Cell Lung Cancer
More than 135 companies are actively developing over 150 therapies for non-small cell lung cancer (NSCLC). The latest report identifies major players including AbbVie, Pfizer, and Bayer.
Market research firm DelveInsight reports that over 135 companies are currently engaged in the development of more than 150 potential therapies for non-small cell lung cancer (NSCLC). The report details ongoing clinical and non-clinical development initiatives, covering various stages of drug discovery.
The research includes numerous major pharmaceutical companies such as AbbVie, Pfizer, Bayer, Eli Lilly, Merck, and Bristol-Myers Squibb, alongside several smaller biopharmaceutical firms. These entities are exploring diverse approaches, including novel molecule types and administration routes, aiming to improve treatment outcomes for NSCLC patients.
Promising therapies under development include Daiichi Sankyo's datopotamab deruxtecan and Novartis's JDQ443. These, among many other drug candidates, aim to target molecular mechanisms that drive cancer progression. Companies are also forming strategic partnerships, such as the licensing agreement between BridgeBio Pharma and Bristol Myers Squibb for the development of the BBP-398 inhibitor.
The report underscores the demand for new treatment modalities, as NSCLC accounts for the majority of lung cancer cases. Despite significant development activity, many potential therapies remain in preclinical or early clinical phases, highlighting the continued importance of research and development.